PT  - JOURNAL ARTICLE
AU  - Farzad Moazed
AU  - Lauren Chun
AU  - Michael A Matthay
AU  - Carolyn S Calfee
AU  - Jeffrey Gotts
TI  - Assessment of industry data on pulmonary and immunosuppressive effects of IQOS
AID  - 10.1136/tobaccocontrol-2018-054296
DP  - 2018 Nov 01
TA  - Tobacco Control
PG  - s20--s25
VI  - 27
IP  - Suppl 1
4099  - http://tobaccocontrol.bmj.com/content/27/Suppl_1/s20.short
4100  - http://tobaccocontrol.bmj.com/content/27/Suppl_1/s20.full
SO  - Tob Control2018 Nov 01; 27
AB  - Introduction Heated tobacco products are being touted as novel reduced-harm tobacco products by tobacco companies. In the USA, Philip Morris International submitted a modified risk tobacco product (MRTP) application to the US Food and Drug Administration in 2016 in which it purports that its heated tobacco product, I-Quit-Ordinary-Smoking (IQOS), is associated with reduced harm compared with conventional cigarettes.Methods We reviewed Philip Morris International’s MRTP application to assess the pulmonary and immune toxicities associated with IQOS use in both animal and human studies.Results Among rats exposed to IQOS, there was evidence of pulmonary inflammation and immunomodulation. In human users, there was no evidence of improvement in pulmonary inflammation or pulmonary function in cigarette smokers who were switched to IQOS.Conclusion IQOS is associated with significant pulmonary and immunomodulatory toxicities with no detectable differences between conventional cigarette smokers and those who were switched to IQOS in Philip Morris International’s studies. Philip Morris International also failed to consider how dual use and secondhand aerosol exposure may further impact, and likely increase, the harms associated with these products.